



IFW  
\$

PATENT  
ATTORNEY DOCKET NO. 04843/118003

Certificate of Mailing: Date of Deposit: January 17, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon  
Printed name of person mailing correspondence

*Susan M. Cannon*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John L. Neumeyer et al. Art Unit: 1625  
Serial No.: 10/716,100 Examiner: Desai, Rita J.  
Filed: November 18, 2003 Customer No.: 21559  
Title: MIXED KAPPA/MU OPIOIDS AND USES THEREOF

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: January 17, 2006

Jeffrey J. Ellison  
Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Jeffrey J. Ellison, Reg. No. 51,649,  
for Paul T. Clark

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/118003
	Serial No.	10/716,100
	Applicant	Neumeyer et al.
	Filing Date	November 18, 2003
	Group	1625
	IDS Filed	January 17, 2006
Customer No.	21559	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	3,853,889	Dec. 10, 1974	Monkovic et al.			
	3,936,462	Feb. 3, 1976	Albertson			
	3,959,290	May 25, 1976	Monkovic et al.			
	4,154,932	May 15, 1979	Montzka et al.			
	4,228,285	Oct. 14, 1980	Montzka et al.			
	4,246,413	Jan. 20, 1981	Montzka et al.			
	4,277,605	Jul. 7, 1981	Buyniski et al.			
	6,166,211	Dec. 26, 2000	Cain et al.			
	US 2005/0045562 A1	Mar. 11, 2004	Sapala et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 2004/045562 A2	Jun. 3, 2004	WIPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Albertson et al., "Benzomorphans. Structure of a Position Isomer," <i>J. Med. Chem.</i> , 21:471-474 (1978).					
	Archer et al., "Pentazocine. Strong Analgesics and Analgesic Antagonists in the Benzomorphan Series," <i>J. Med. Chem.</i> 7:123-127 (1964).					
	Berke et al., "Addiction, Dopamine, and the Molecular Mechanisms of Memory," <i>Neuron</i> 25:515-532 (2000).					
	Bidlack et al., "8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan," <i>J. Pharm. Exp. Ther.</i> 302:374-380 (2002).					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Fawzi et al., "SCH-202676: An Allosteric Modulator of Both Agonist and Antagonist Binding to G Protein-Coupled Receptors," <i>Mol. Pharm.</i> 59:30-37 (2001).					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/118003
	Serial No.	10/716,100
	Applicant	Neumeyer et al.
	Filing Date	November 18, 2003
	Group	1625
	IDS Filed	January 17, 2006
	Customer No.	21559

	Gutkowska et al., "The Synthesis and Pharmacological Activity of Two New Derivatives of Benzazocine," <i>Pol. J. Pharmacol. Pharm.</i> 43:153-163 (1991).
	Hayes et al., "A Series of Novel, Highly Potent and Selective Agonists for the $\kappa$ -opioid Receptor," <i>Br. J. Pharmacol.</i> 101:944-947 (1990).
	Hayes and Birch, "Reversal by $\beta$ -Funaltrexamine and 16-Methyl Cyprenorphine of the Antinociceptive Effects of Opioid Agonists in the Mouse and Guinea-Pig," <i>Neuropharmacology</i> 27:813-816 (1988).
	Jordan et al., "Opioids and Their Complicated Receptor Complexes," <i>Neuropsychopharmacology</i> 23:S5-S18 (2000).
	Kaczor and Matusiuk, "Non-peptide Opioid Receptor Ligands - Recent Advances. Part I - Agonists," <i>Curr. Med. Chem.</i> 9:1567-1589 (2002).
	Lambert et al., "Analgesics and Narcotic Antagonists in the Benzomorphan and 8-Oxamorphinan Series. 5.," <i>J. Med. Chem.</i> 21:423-427 (1978).
	Lemaire et al., "14- $\beta$ -Methyl-8-Oxacyclorphan (BC-3016), a Morphinan Derivative with High Affinity for Kappa Opioid Receptor: Comparison with Dynorphin-A(1-13)," 64:707-711 (1986).
	May and Eddy, "Interesting Pharmacological Properties of the Optical Isomers of $\alpha$ -5,9-Diethyl-2'-hydroxy-2-methyl-6,7-benzomorphan," <i>J. Med. Chem.</i> 9:851-852 (1966).
	McElroy et al., "Synthesis, Antinociceptive Activity, and Opioid Receptor Profiles of 10-Substituted-6-oxamorphinans," <i>J. Chem. Soc. Perkin Trans. 1</i> 1563-1571 (1990).
	McKenzie et al., "5-Aryl-3-azabicyclo[3.2.0]heptan-6-one Ketals, Compounds with Morphine-Like Analgesic Activity," <i>J. Med. Chem.</i> 27:628-632 (1984).
	John L. Neumeyer "Mixed Kappa-Mu Opioids: Synthesis and Evaluation" Abstract for NIH Grant Number: 2R01DA014251-04A1, September 1, 2001.
	Szmuszkowicz, "U-50,488 and the $\kappa$ Receptor Part II": 1991-1998," <i>Progress in Drug Research</i> 53:1-51 (1999).
	Ucar et al., "2 (3H) -Benzoxazolone and 2(3H)-Benzothiazolone Derivatives: Novel, Potent and Selective $\sigma_1$ Receptor Ligands," <i>Eur. J. Pharmacol.</i> 355:267-273 (1997).
	Wentland et al., "3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties," <i>Bioorg. Med. Chem. Lett.</i> 11:1717-1721 (2001).
	Wentland et al., "8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines," <i>Bioorg. &amp; Med. Chem. Lett.</i> 11:623-626 (2001).
	Wise, "Neurobiology of Addiction," <i>Curr. Opin. Neurobiol.</i> 6:243-251 (1996).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/118003
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>		Serial No.	10/716,100
		Applicant	Neumeyer et al.
		Filing Date	November 18, 2003
		Group	1625
		IDS Filed	January 17, 2006
		Customer No.	21559

	Yokoyama et al., "Syntheses, Analgetic Activity, and Physical Dependence Capacity of 5-Phenyl-6,7-benzomorphan Derivatives," <i>J. Med. Chem.</i> 22:537-553 (1979).
	Zhang et al., "Synthesis of Amino-thiazole Derived Morphinans," <i>Tetrahedron Lett.</i> 44:6459-6462 (2003).
	Zimmerman and Leander, "Opioid Antagonists: Structure Activity Relationships," <i>NIDA Res. Monogr.</i> 96:50-60 (1990).

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.</p>	